STOCK TITAN

Seres Therapeutics Inc - MCRB STOCK NEWS

Welcome to our dedicated news page for Seres Therapeutics (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seres Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seres Therapeutics's position in the market.

Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) will host a conference call to discuss Q4 and full year 2023 results and provide a business update on March 5, 2024. Investors can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences earnings
-
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) CEO to participate in a panel discussion at Cowen 44th Annual Health Care Conference. The event will be webcasted and archived for 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) appoints Marella Thorell as CFO, succeeding David Arkowitz. Thorell brings extensive industry experience to drive financial strategy and advance product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
management
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) granted inducement equity grants to a new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units covering 22,500 shares of its common stock. The options have an exercise price of $1.21 per share and will vest over time, in accordance with the terms of the Inducement Plan adopted by the company's board of directors in December 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced preliminary net sales of approximately $10.4 million for the fourth quarter of 2023. The company also reported significant adoption of VOWST, the first FDA approved orally administered microbiome therapeutic, with 2,833 patient enrollment forms received and 2,015 new patient starts. Additionally, SER-155 Phase 1b placebo-controlled Cohort 2 data readout is anticipated in the third quarter of 2024. Seres is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company also received US FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
clinical trial
-
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via audio webcast and replay, offering investors valuable insights into the company's future plans and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced preliminary clinical data from a Phase 1b study of SER-155 for adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) at the 65th ASH Annual Meeting. The study aims to prevent enteric-derived infections, blood stream infections, and reduce the incidence of graft-versus-host disease (GvHD) by modulating immune responses in the gastrointestinal tract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics, ticker symbol MCRB, will participate in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. The audio webcast will be available on the company's website, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics, Inc. reports Q3 2023 financial results, including VOWST net sales of $7.6 million. The company has received over 1,500 patient enrollment forms for VOWST since FDA approval. They also announced a strategic restructuring to focus on VOWST growth and reduce costs, resulting in a workforce reduction of 41% and anticipated annual cash savings of $75-$85 million in 2024. The restructuring is expected to support the company's operations into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.28%
Tags
earnings
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will release its third quarter 2023 financial results on November 2, 2023. A conference call with investors will be held at 8:00 a.m. ET. The webcast replay will be available on the Seres website for approximately 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
earnings
Seres Therapeutics Inc

Nasdaq:MCRB

MCRB Rankings

MCRB Stock Data

158.99M
100.97M
6.65%
69.54%
12.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About MCRB

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.